- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04464447
Feasibility and Pilot Testing of Group-based ACT for Adolescents With Functional Somatic Syndromes (AHEAD)
June 9, 2021 updated by: University of Aarhus
Feasibility of Group-based Acceptance and Commitment Therapy for Adolescents (AHEAD) With Functional Somatic Syndromes: A Pilot Study
Recurrent and impairing functional somatic syndromes (FSS) are common in adolescents.
Despite a high need for care, empirically supported treatments are lacking for youth.
The aim of the uncontrolled was to assess feasibility and treatment potential of group-based Acceptance and Commitment Therapy (ACT) in a generic treatment approach for adolescents with multiple FSS i.e. "ACT for Health in Adolescents" (AHEAD).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years to 15 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Bodily Distress Syndrome, multi-organ type of at least 12 months' duration
- Raised since early childhood in Denmark or born by Danish parents
- Understand, speak and read Danish
- Moderate or severe impairment
Exclusion Criteria:
- Acute psychiatric disorder demanding other treatment, or if the patient is suicidal.
- A lifetime diagnosis of psychosis, mania or depression with psychotic symptoms (ICD-10: F20-29, F30-31, F32.2, F33.3), serious cognitive deficits or developmental disorders such as mental retardation and autism (ICD-10: F70, F84)
- Substance abuse of e.g. narcotics, alcohol or medication.
- Pregnancy at time of inclusion
- Not able to participate in group-based treatment, e.g. patients with severe ADHD (ICD-10: F90), severe social phobia (ICD-10: F40.1) or conduct disorder (ICD-10: F91)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Group-based Acceptance and Commitment Therapy
Group-based Acceptance and Commitment Therapy (ACT) for adolescents presenting with multiple functional somatic syndromes.
|
The treatment "ACT for Health in Adolescents" (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module.
Six to eight patients participate in each treatment Group.
An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Short Form Health Survey-36 (SF36) (Assessment of an aggregate score measuring physical health)
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Questionnaire, patient rated.
Physical health measured with aggregate scores of the scales PF (physical functioning), BP (bodily pain) and VT (vitality).
Score range 15-65.
Higher scores indicating a higher degree of self-rated physical health.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Bodily Distress Syndrome checklist (BDS checklist)
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Questionnaire, patient rated.
Assessment of symptom severity.
Score range 0-100.
Higher score indicating a higher degree of symptom severity.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
|
Change in Limitation index Questionnaire
Time Frame: At baseline (i.e. at clinical assessment), before psychiatric consultation (approximately 2 weeks after clinical assessment), and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
Questionnaire, patient rated.
Assessment of symptom interference.
Score range 0-36 with higher score indicating a higher degree of limitation.
|
At baseline (i.e. at clinical assessment), before psychiatric consultation (approximately 2 weeks after clinical assessment), and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
|
Change in Whiteley 7
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Questionnaire, patient rated.
Assessment of illness worry.
Overall mean item score range from 0-4 with higher scores indicating a higher degree of illness worry.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
|
Change in SCL-8 Questionnaire
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Questionnaire, patient rated.
Assessment of emotional distress.
Overall mean score range from 0-4 with higher scores indicating a higher degree of emotional distress.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
|
Change in SF-36 PCS
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Aggregate score from questionnaire - physical component summary.
Patient rated.
The aggregate score has a mean of 50 and a SD of 10, but no range.
Higher scores indicate better physical health.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
|
Change in SF-36 MCS
Time Frame: At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
Aggregate score from questionnaire - mental component summary.
Patient rated.
The aggregate score has a mean of 50 and a SD of 10, but no range.
Higher scores indicate better mental health.
|
At baseline (i.e. at clinical assessment), and at 2, 4, 5, and 8 months (corresponding to group start, 8th, 9th module and follow up meeting)
|
|
Change in IPQ-R Illness Perceptions Questionnaire
Time Frame: At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
Questionnaire, patient rated.
Treatment target.
Score range 0-80 with higher scores reflecting a more maladaptive view of the illness.
|
At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
|
Change in BRIQ Behavioural Responses to Illness Questionnaire
Time Frame: At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
Questionnaire, patient rated.
Assessment of illness related behaviour.
Treatment target.
Measures two dimensions of illness behaviour i.e. limiting behaviour (score range 7-35) and all-or-nothing behaviour (score range 6-30).
Higher scores indicate a higher degree of maladaptive behaviour.
|
At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
|
Change in AFQ-Y8 (Avoidance and Fusion Questionnaire in Youth)
Time Frame: At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
Questionnaire, patient rated.
Assessment of psychological flexibility.
Treatment target.
Score range 0-32 with higher scores relfecting a higher degree of psychological inflexibility.
|
At baseline (i.e. at clinical assessment) and at 2, 3, 4, 5, and 8 months (corresponding to before therapy, after 4th, 8th, 9th module and at follow up meeting)
|
|
PGIC (Patient Global Impression of Change)
Time Frame: At 8 months corresponding to at follow up meeting
|
Questionnaire, patient rated.
7 point scale with answers ranging from "no change or condition gotten worse" to "a great deal better and a considerable improvement that has made all the difference".
|
At 8 months corresponding to at follow up meeting
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified version of ESQ Experience of Service Questionnaire
Time Frame: At 8 months corresponding to at follow up meeting
|
Questionnaire, patient rated.
Assessment of their treatment experience.
|
At 8 months corresponding to at follow up meeting
|
|
Questions concerning close relatives' satisfaction with information meeting
Time Frame: At meeting for close relatives corresponding to approximately 1 week after start of group therapy (i.e. at 2 months)
|
Questions regarding specific meeting content and possibility of free text comments.
Rated by close relatives.
|
At meeting for close relatives corresponding to approximately 1 week after start of group therapy (i.e. at 2 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Charlotte U Rask, MD, PhD, Aarhus University and during study the Research Clinic for Functional Disorders and Psychosomatics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2013
Primary Completion (Actual)
April 15, 2015
Study Completion (Actual)
April 24, 2015
Study Registration Dates
First Submitted
June 27, 2020
First Submitted That Met QC Criteria
July 6, 2020
First Posted (Actual)
July 9, 2020
Study Record Updates
Last Update Posted (Actual)
June 14, 2021
Last Update Submitted That Met QC Criteria
June 9, 2021
Last Verified
June 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- AHEAD pilot
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Has not been incorporated in the consent from the patients.
However, some data will be available upon request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Disorder
-
Medical University of GrazRecruitingFunctional Neurological Disorder | Functional Movement DisorderAustria
-
King's College Hospital NHS TrustRecruiting
-
Nantes University HospitalCompletedDentofacial Functional DisorderFrance
-
University of VirginiaChild Neurology FoundationActive, not recruitingFunctional Neurological Symptom Disorder | Functional Neurological Disorder | Functional Movement DisorderUnited States
-
University Hospital Schleswig-HolsteinCompletedFunctional Blood Flow DisorderGermany
-
South West London and St George's Mental Health...CompletedFunctional Neurological Symptom DisorderUnited Kingdom
-
University Hospital, Basel, SwitzerlandRecruitingFunctional Neurological DisorderSwitzerland
-
Fundación Pública Andaluza para la gestión de la...Fundación CaserCompletedFunctional Neurological Disorder | Functional Movement DisorderSpain
-
University of Colorado, DenverRecruitingFunctional Neurological DisorderCanada
-
Western University, CanadaNot yet recruitingFunctional Movement DisorderCanada
Clinical Trials on Acceptance and Commitment Therapy
-
Anne Roche, MACompletedQuality of Life | AgingUnited States
-
Universidade Federal do ParanáActive, not recruitingObsessive-Compulsive DisorderBrazil
-
Ataturk UniversityNot yet recruitingChronic Mental DisordersTurkey
-
Universiti Sains MalaysiaRecruitingBreast Cancer FemaleMalaysia
-
University of CyprusNot yet recruitingDepression | Anxiety Disorders | Post Traumatic Stress Disorder
-
University of TromsoThe Royal Norwegian Ministry of HealthCompleted
-
University of NottinghamNottinghamshire Healthcare NHS Foundation Trust; Derbyshire Healthcare NHS...Completed
-
University of Alabama at BirminghamWithdrawn
-
Nova Scotia Health AuthorityCompleted
-
VA Office of Research and DevelopmentCompletedChronic Pain | Mild Traumatic Brain Injury | Distress-based PsychopathologyUnited States